Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
Hematological Malignancies
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 546 (planned)
- Started
- Sep 9, 2024
- Main results expected
- Jul 2039
- Fully finished
- Jul 2039
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of participants with targeted adverse events (AEs)
Measured over: From infusion up to 15 years
Percentage of participants with detectable CAR transgene levels in peripheral blood
Measured over: From infusion up to 15 years
Percentage of participants with serious AEs (SAEs) considered related to the Galapagos CAR T-cell therapy
Measured over: From infusion up to 15 years
Percentage of participants with at least 1% of T-cells in the blood sample or positive new malignancies
Measured over: From infusion up to 15 years
Percentage of participants with detectable replication-competent lentivirus (RCL) in peripheral blood
Measured over: From infusion up to 15 years
Percentage of participants who died with causes
Measured over: From infusion up to 15 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06652633 · record last updated 2026-07-13 · checked 2026-11-09 15:47 UTC